0
Editorials |

A Unified Front Against COPDA Unified Front Against COPD: Clinical Practice Guidelines From the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society

Nicola A. Hanania, MD, FCCP; Darcy D. Marciniuk, MD, FCCP; for the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society
Author and Funding Information

From the Section of Pulmonary and Critical Care Medicine (Dr Hanania), Baylor College of Medicine; and Division of Respirology (Dr Marciniuk), Critical Care and Sleep Medicine, University of Saskatchewan.

Correspondence to: Darcy D. Marciniuk, MD, FCCP, Division of Respirology, Critical Care and Sleep Medicine, Royal University Hospital, 5th Floor Ellis Hall, 103 Hospital Dr, Saskatoon, SK, S7N 0W8, Canada; e-mail: darcy.marciniuk@usask.ca


Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Drs Hanania and Marciniuk were coauthors on the guideline discussed, representing the American College of Chest Physicians. Dr Hanania has received research grant support (paid to his institution) from GlaxoSmithKline, Boehringer Ingelheim GmbH, Novartis, Pfizer Inc, and Sunovion Pharmaceuticals Inc. He has received honoraria for serving on the speaker’s bureau of GlaxoSmithKline, AstraZeneca, and Sunovion Pharmaceuticals Inc and for serving as a consultant or on an advisory board for GlaxoSmithKline, Novartis, Pfizer Inc, Boehringer Ingelheim GmbH, Pearl Therapeutics Inc, and Sunovion Pharmaceuticals Inc. Dr Marciniuk has received research funding (paid to his institution) from AstraZeneca, Boehringer Ingelheim GmbH, Canadian Agency for Drugs and Technology in Health, Canadian Institute of Health Research, GlaxoSmithKline, Lung Association of Saskatchewan, Novartis, Nycomed, Pfizer Inc, Saskatchewan Health Research Foundation, Saskatchewan Ministry of Health, and Merck/Schering-Plough. He has participated on advisory boards, undertaken consulting, and provided continuing education for AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline, Health Canada, Health Quality Council, Novartis, Nycomed, Pfizer Inc, Public Health Agency of Canada, Saskatchewan Medical Association, and Saskatoon Health Region.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).


© 2011 American College of Chest Physicians


Chest. 2011;140(3):565-566. doi:10.1378/chest.11-1152
Text Size: A A A
Published online

Extract

COPD is one of the world’s leading causes of morbidity and mortality. Currently the fifth leading cause of death worldwide, it is predicted that COPD will become the third leading cause of death by the year 2020.1-4 In fact, COPD already has surpassed cerebrovascular disease to become the third leading cause of death in the United States.5 In addition, COPD is now recognized as a life-limiting illness that imposes significant symptom burden on those with the disease. The varied and diverse pathology of COPD, which is caused by cigarette smoke exposure in the majority of patients, typically involves multiple components, including small airway inflammation and remodeling, mucociliary dysfunction, and lung architecture damage. These pathologic changes lead to airflow limitation, resulting in gas trapping and hyperinflation, with resultant disability and handicap.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543